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Abstract
Background: Mutations in the SPG4 gene (spastin) and in the SPG3A gene (atlastin) account for
the majority of 'pure' autosomal dominant form of hereditary spastic paraplegia (HSP). Recently,
mutations in the REEP1 gene were identified to cause autosomal dominant HSP type SPG31. The
purpose of this study was to determine the prevalence of REEP1 mutations in a cohort of 162
unrelated Caucasian index patients with 'pure' HSP and a positive family history (at least two
persons per family presented symptoms).
Methods: 162 patients were screened for mutations by, both, DHPLC and direct sequencing.
Results: Ten mutations were identified in the REEP1 gene, these included eight novel mutations
comprising small insertions/deletions causing frame shifts and subsequently premature stop codons,
one nonsense mutation and one splice site mutation as well as two missense mutations. Both
missense mutations and the splice site mutation were not identified in 170 control subjects.
Conclusion: In our HSP cohort we found pathogenic mutations in 4.3% of cases with autosomal
dominant inheritance. Our results confirm the previously observed mutation range of 3% to 6.5%,
respectively, and they widen the spectrum of REEP1 mutations.
Background
Hereditary spastic paraplegia (HSP) is a clinically and
genetically heterogeneous disorder characterised by pro-
gressive spasticity, weakness and hyperreflexia of the
lower limbs. Clinically it is divided into a 'pure' or uncom-
plicated form with progressive spasticity as major symp-
tom, associated with brisk reflexes, muscle weakness,
positive Babinski's sign and urinary urgency as well as a
'complicated' form accompanied with other neurological
abnormalities, i.e. retinal pigmentation, mental retarda-
tion, deafness, optic atrophy or seizures [1,2]. So far, over
35 loci have been identified for autosomal dominant,
recessive and X-linked HSP. The autosomal dominant
HSP is indeed the main mode of inheritance, accounting
for about 70–80% of all HSPs in Western countries, and it
is predominantly associated with pure forms [1]. The
occurrence of recessive HSP amount to 20–30%, whereas
X-linked HSP is very rare.
In 15–40% of families with the 'pure' autosomal domi-
nant form of HSP, DNA sequence analysis identified a
mutation in the SPG4 gene (spastin) [1] and in ~10% a
mutation in the SPG3A gene (atlastin) [2]. In further 18–
20% of families gross deletions (of one or more exons) of
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the  SPG4  gene have been found [3,4]. No pathogenic
gross deletions in the SPG3A  gene have been demon-
strated so far. Mutations in the REEP1 gene (SPG31) were
analysed in two studies [5,6], and pathogenic mutations
were identified in 6.5% and 3% of cases, respectively,
including one large multi-exonic duplication [5,6].
Methods
Subjects
162 unrelated patients with clinical symptoms of 'pure'
HSP and a positive family history (at least two persons per
family presented symptoms) were analysed in this study.
Mutations in the SPG4 gene were excluded in all patients
and in SPG3A in 152 of the 162 patients. Gross deletions
were excluded in half of the patients by MLPA. Control
samples from 170 healthy German blood donors were
collected at the Department of transfusion medicine of
the University Hospital in Essen (Germany). DNA was
extracted from EDTA-anticoagulated peripheral blood by
using a standard salting-out method [7]. This study was
approved by the institutional review board, informed
consent was obtained from all subjects, and the Declara-
tion of Helsinki protocols were followed.
PCR
Screening of the entire coding region of the REEP1 gene
(seven exons including the flanking intronic sequence, at
least 40 bp from each end) was performed using polymer-
ase chain reaction (PCR) with consecutive DHPLC analy-
sis. PCR reactions for exon 1 were performed in a total
volume of 10 μl, containing 60 ng DNA, 10 mmol of each
dNTP DEAZA (Roche, Mannheim, Germany), 3 mmol
MgCl2  (Qiagen, Hilden, Germany) 10 pmol of each
primer, 0.25 U Taq polymerase Hotstar Taq Plus (Qiagen,
Hilden, Germany), DMSO 5% and 10 × buffer (contains
15 mM MgCl2); (Qiagen, Hilden, Germany). PCR reac-
tions for exons 2 to 7 were performed in a total volume of
12.5 μl, containing 100 ng DNA, 2.5 mmol of each dNTP,
2 mmol MgCl2, 10 pmol of each primer, 0.5 U Taq
polymerase (Genecraft, Lüdinghausen, Germany) and 10
× buffer BioTherm without MgCl2  (Genecraft,
Lüdinghausen, Germany). Thermal cycling was per-
formed in a Biometra TGradient (Whatman, Maidstone,
Kent, England). For each of the 7 PCR fragments, primer
sequences and annealing temperatures are shown in Table
1.
DHPLC analyses
DHPLC is a chromatographic mutation analysis tech-
nique that is based on temperature-dependent separation
of DNA from PCR-amplified DNA fragments [8]. Differ-
ent schemes for mutation screening were performed using
DHPLC, i.e. the WAVE® DNA Fragment Analysis System
(Transgenomic, Glasgow, UK) as described [9] with the
analysis software Navigator Software (Transgenomic,
Glasgow, UK).
PCR mixes were applied in double and four-fold amount
(conditions see above) and were performed in total vol-
umes of 25 μl (exons 2 to 7) or 40 μl (exon 1). Addition-
ally the PCR amplicons were heated up to 94°C for 3 min
and cooled slowly down to 20°C (30 sec) in a thermocy-
cler (Biometra TGradient, Whatman, Maidstone, Kent,
England) before loading onto the WAVE column. The
amount of one injection per PCR sample was 5 μl. The
probes were analyzed with variable retention times (Table
2) and compared to a chromatogram of a healthy control
sequence variation. A variant in exon 3 (c.164C>A,
p.Thr55Lys) was genotyped using the WAVE analysis sys-
tem (no restriction enzyme available).
Table 1: Primer sequences and annealing temperatures 
Amplified segment Primer
Annealing 
temperature
SPG31 Ex 1 F1: ACCAGCTCACCGCCCAATC
R1: GTATTAATAGCCCGAGCCACTGG
56°C/30 cycles
SPG31 Ex 2 F2: AAGATAGAGGTGCCCAAGGATG
R2: TGAGAACTGTGATGAAGGAACTCC
58°C/28 cycles
SPG31 Ex 3 F3: GGAAGGATAGGGAGAAGGCTAC
R3: CCTGAGGTGAGGTTTGAGGC
58°C/28 cycles
SPG31 Ex 4 F4: TTCAAAAGGGCAGTGTTGCTG
R4: ATGACTTGCTGGAGGCAAATGA
58°C/28 cycles
SPG31 Ex 5 F5: GCCAAGCCCAATGCTCAGAG
R5: GGTCCTTAGCCTGTTCTGTGTGG
60°C/28 cycles
SPG31 Ex 6 F6: AGCTCCCTCTTGGCCTTTGTC
R6: GGACTGGGCCTCTCTCAATGA
58°C/28 cycles
SPG31 Ex 7 F7: GAGATTCAGGGAGACCCCAGC
R7: GGAGAGAGAAAAGGCCATGTTTG
60°C/28 cycles
(F: forward primer; R: reverse primer)BMC Medical Genetics 2008, 9:71 http://www.biomedcentral.com/1471-2350/9/71
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DNA sequencing
DNA samples with peculiar separation behaviour in
DHPLC analysis were directly sequenced using the
AMPure- (1st purification) and CleanSeq-Kit (2nd-purifica-
tion; Beckman, Krefeld, Germany) as described in the
manufacturer's instructions on an automated sequencer
(MegaBace 1000, GE Healthcare, Freiburg, Germany; and
ABI PRISM 377, DNA Sequencer).
RFLP
Two newly identified sequence variations, c.320T>C,
p.Leu107Pro (exon 5) and c.105+6T>C (intron 2), as well
as a mutation in the 3'UTR (c.606+43G>T) were geno-
typed by restriction enzyme digestion. Patient and control
samples were amplified using the same primers and con-
ditions as described above. 12.5 μl of PCR products were
digested with 0.31 units of Bbv I (intron 2), 0.25 units of
Msp I (exon 5) and 0.46 units of BsuRI (3'UTR) at 37°C
for 3 hours. The fragments were separated on 2% agarose
gels in 1 × TBE buffer (30 min, 200 V) and visualised using
ethidium bromide.
In silico analysis
Putative functional and splicing effects of the three
unclear sequence variations were investigated using the
programs ESEfinder release 3.0 [10] and NNSPLICE 0.9
software [11]. ESEfinder identifies putative exon splicing
enhancers responsive to the human SR proteins SF2/ASF,
SC35, SRp40 and SRp55. NNSPLICE is based on a neural
network to predict the presence and relative efficiencies of
donor and acceptor sites.
Results and Discussion
In this study we analysed a cohort of 162 patients with the
'pure' autosomal-dominant form of HSP for mutations in
the REEP1 gene. In addition, 170 healthy control subjects
were analysed for the newly identified sequence varia-
tions.
We identified nucleotide exchanges in all exons in com-
parison to the reference sequence except for exon 1. Ten
mutations which include 7 (4.3% of cases) pathogenic
mutations (small insertions/deletions, nonsense- and
3'UTR exchanges) and three (1.9% of cases) novel
sequence variations (missense and splice site) were iden-
tified. Six of these seven pathogenic mutations (three
small out of frame deletions, two small out of frame inser-
tion and a nonsense mutation) as well as three unclear
sequence variations (two missense and one splice site)
have not been described before (Table 3). In detail, we
newly identified two small deletions of one nucleotide
(c.60delG and c.478delA), one deletion of eight nucle-
otides (c.340_347delAGTTACGA), an insertion of one
nucleotide (c.419_420insG), an insertion of two nucle-
otides (c.183_184insCT) and a nucleotide exchange
which leads to a premature stop codon (c.C345A;
p.Try115X). Because DHPLC mutation screening tech-
nique is not 100% sensitive [12], sequence alterations
might be missed, which would increase the frequency of
REEP1 mutations. In three cases more than one sympto-
matic family member was analysed. There was one more
family member tested for the deletions in exon 6
(c.478delA) and in exon 2 (c.60delG) in each case and
two additional family members for the insertion
(c.419_420insG). The three families are composed of
father and son, father and daughter as well as mother and
two children. All affected family members show the same
mutation. In our HSP cohort the mean age of onset is in
the early twenties (3 to 50 years). Two novel variations
represent missense mutations (c.164C>A, p.Thr55Lys,
c.320T>C, p.Leu107Pro) and the other one a splice site
variation in the donor splice site (c.105+6 T>C). The
splice site prediction program NNSPLICE 0.9 calculates a
score of 0.98 for the wild-type donor of exon/intron 2.
The c.105+6 T>C substitution lowers the donor consensus
value to 0.88, probably leading to preferential usage of a
cryptic donor present 29 bp downstream in intron 2 with
a score of 0.64 [gagtcagGTcaggtg].
In silico analysis with the ESE-finder program revealed that
c.164C>A abolishes strong exon splicing enhancer sites
for SF2/ASF, SRp40 and SRp55 as well as it leads to a new
strong site for SRp55. For c.320T>C the score for a poten-
Table 2: WAVE conditions
Amplified segment WAVE: oven temperature time shift
SPG31 exon 1 65°C/70°C no
SPG31 exon 2 54,5°C/57°C/58°C no
SPG31 exon 3 59°C/63°C 63°C: 2,0
SPG31 exon 4 56°C/57°C/59°C 59°C: 1,0
SPG31 exon 5 58°C/61,5°C/64°C no
SPG31 exon 6 61°C/62°C/63°C no
SPG31 exon 7 58,6°C/60,6°C no
Table 3: Mutations found in REEP1
Nucleotide exchange Amino acid exchange
SPG31 exon 1 none
SPG31 exon 2 c.60delG p.6fsX
c.105+6T>C
SPG31 exon 3 c.164C>A p.Thr55Lys
SPG31 exon 4 c.183_184insCT p.7fsX
SPG31 exon 5 c.320T>C p.Leu107Pro
c.340_347delAGTTACGA p.69fsX,
c.345C>A p.Try115X
SPG31 exon 6 c.419_420insG p.45fsX
c.478delA p.62fsX
SPG31 exon 7 c.606+43G>T*
* previously describedBMC Medical Genetics 2008, 9:71 http://www.biomedcentral.com/1471-2350/9/71
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tial binding site for the splicing factors SRp40 strongly
increases when substituting the T by C. Thus these
sequence exchanges could result in defective splicing of
introns, exon skipping, frameshift and introduction of
another premature termination codon. In that case, all
sequence variations found would be in line with the con-
cept of haploinsufficiency. Unfortunately, we could not
test this hypothesis, because, as REEP1 is not expressed in
peripheral blood cells [6], we were not able to perform
RNA analyses. Furthermore, we also had no further rela-
tives with symptoms of HSP available to be investigated.
Segregation analysis for these sequence variations is advis-
able in order to confirm the pathogenetic relevance. Yet,
all unclear sequence variations were absent in 170 healthy
controls.
In addition, we identified also common polymorphisms
in exon 2 to exon 5 in many cases, which are listed in
Table 4. Additionally, we found two further polymor-
phisms in intron 6 (c.595T>G) and the 3'UTR
(c.606+155T>C) in four of the 162 patients in hetero-
zygous state (allele frequency 1.2%).
Conclusion
Having identified pathogenic mutations in the REEP1
gene in 4.3% of our HSP cases, previous mutation fre-
quency determinations (6.5% and 3%, respectively) are
substantiated, and hence the spectrum of REEP1 muta-
tions is complemented. Mutations in the REEP1  gene
appear as the third most frequent cause in families with
the 'pure' autosomal dominant form of HSP. Therefore
mutation analysis in the REEP1 gene should be included
in the comprehensive care for patients with the 'pure'
autosomal dominant form of HSP.
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Table 4: Polymorphisms found in REEP1
rs-number/Polymorphism
SPG31 intron 1 rs1863059
SPG31 intron 2 rs1863058
rs1863056
SPG31 exon 4 rs2276625
SPG31 intron 5 rs12988844
SPG31 intron 6 c.595-19T>G, G allele: 1,2%
SPG31 3'UTR c.606+155T>C, C allele: 1,2%